The effect of etoposide on human CFU-GM

Etoposide is being used increasingly in the treatment of a variety of malignant conditions and in conjunction with autologous bone marrow transplantation. We have examined the effect of the drug on human CFU-GM as an indication of the response of these bone marrow progenitor cells to measured plasma...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 52; no. 4; pp. 613 - 617
Main Authors BAILEY-WOOD, R, DALLIMORE, C. M, LITTLEWOOD, T. J, BENTLEY, D. P
Format Journal Article
LanguageEnglish
Published Basingstoke Nature Publishing Group 01.10.1985
Subjects
Antineoplastic agents
Biological and medical sciences
Cell Count
Cell Survival - drug effects
Etoposide - pharmacology
General aspects
Granulocytes
Hematopoietic Stem Cells - drug effects
Humans
In Vitro Techniques
Medical sciences
Monocytes
Pharmacology. Drug treatments
Podophyllotoxin - analogs & derivatives
Protein Binding
Serum Albumin
Serum Albumin, Bovine
Antineoplastic agent
Bone marrow
CFU-GM-Cell
Activity toxicity relation
Online AccessGet full text

Cover

More Information
Summary:Etoposide is being used increasingly in the treatment of a variety of malignant conditions and in conjunction with autologous bone marrow transplantation. We have examined the effect of the drug on human CFU-GM as an indication of the response of these bone marrow progenitor cells to measured plasma concentrations. When etoposide is present in the routine assay for 7 days, 50% growth of colony-forming CFU-GM occurs at a concentration of 0.0098 micrograms ml-1. When bovine serum albumin or human serum albumin is present this value is increased to 0.042 and 0.375 micrograms ml-1. Protein binding therefore plays an important part in modifying in vitro response and possibly in vivo response of these progenitor cells to etoposide.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1985.234